1. Background
2. Objectives
3. Patients and Methods
3.1. Study Area and Subjects
3.2. Specimens and Bacterial Identification
3.3. Antimicrobial Susceptibility Testing
4. Results
| Years | Total Samples | Positive Cultures |
|---|---|---|
| 2011 - 2012 | 302 | 51 (16.9) |
| 2012 - 2013 | 189 | 23 (12.2) |
| Total | 491 | 74 (15.1) |
a Significance Level: 0.25.
| Isolates | 2011 - 2012 | 2012 - 2013 | Total |
|---|---|---|---|
| G+ | |||
| S. epidermidis | 23 (45.1) | 13 (56.5) | 36 (48.6) |
| CoNS (other than S. epidermidis) | 11 (21.5) | 0 | 11 (14.7) |
| S. aureus | 1 (2) | 0 | 1 (1.4) |
| Enterococcus spp | 1 (2) | 0 | 1 (1.4) |
| Streptococcus spp | 2 (3.9) | 0 | 2 ( 2.7) |
| Total G+ | 38 (74.5) | 13 (56.5) | 51 (68.9) |
| G- | |||
| Pseudomonas spp | 1 (2) | 3 (13) | 4 (5.4) |
| Enterobacter spp | 3 (5.9) | 2 (8.7) | 5 (6.8) |
| Klebsiella spp | 3 (5.9) | 0 | 3 (4.1) |
| E. coli | 4 (7.8) | 1 (4.4) | 5 (6.8) |
| Acinetobacter spp | 2 (3.9) | 4 (17.4) | 6 (8.1) |
| Total G- | 13 (25.5) | 10 (43.5) | 23 (31.1) |
| Total | 51 (68.9) | 23 (31.1) | 74 (100) |
a Data are presented as No. (%).
bP = 0.174, for differences between overall Gram positive and negative isolates (2011-2013).
c G+: overall gram positive isolates; G-: overall gram negative isolates.
a Data are presented as No. (%).
| Isolates/Antibiotics | S. aureus (Total No: 1) | Enterococcus spp. (Total No: 1) | Streptococcus spp. (Total No: 2) | CoNS (other than (S. epidermidis) (Total No: 11) | S. epidermidis (Total No: 36) |
|---|---|---|---|---|---|
| Cloxacillin | |||||
| R | 0 | 1 (100) | 2 (100) | 9 (81.8) | 28 (77.7) |
| I | 0 | 0 | 0 | 0 | 2 (5.6) |
| S | 1 (100) | 0 | 0 | 2 (18.2) | 6 (16.7) |
| Lincomycin | |||||
| R | 0 | 1 (100) | 1 (50) | 9 (81.8) | 30 (83.3) |
| I | 0 | 0 | 0 | 0 | 0 |
| S | 1 (100) | 0 | 1 (50) | 2 (18.2) | 6 (16.7) |
| Chloramphenicol | |||||
| R | 0 | 0 | 0 | 3 (27.3) | 9 (25) |
| I | 0 | 1 (100) | 0 | 0 | 1 (2.8) |
| S | 1 (100) | 0 | 2 (100) | 8 (72.7) | 26 (72.2) |
| Vancomycin | |||||
| R | 0 | 1 (100) | 0 | 0 | 0 |
| I | 0 | 0 | 0 | 0 | 0 |
| S | 1 (100) | 0 | 2 (100) | 11 (100) | 36 (100) |
| Co-trimoxazole | |||||
| R | 0 | 1 (100) | 1 (50) | 7 (63.6) | 31 (86.1) |
| I | 0 | 0 | 0 | 0 | 0 |
| S | 1 (100) | 0 | 1 (50) | 4 (36.4) | 5 (13.9) |
| Ciprofloxacin | |||||
| R | 0 | 1 (100) | 0 | 10 (90.9) | 27 (75) |
| I | 1 (100) | 0 | 0 | 0 | 0 |
| S | 0 | 0 | 2 (100) | 1 (9.1) | 9 (25) |
| Erythromycin | |||||
| R | 1 (100) | 1 (100) | 0 | 11 (100) | 33 (91.7) |
| I | 0 | 0 | 0 | 0 | 0 |
| S | 0 | 0 | 2 (100) | 0 | 3 (8.3) |
| Gentamycin | |||||
| R | 0 | 0 | 0 | 9 (81.8) | 23 (63.9) |
| I | 0 | 0 | 0 | 0 | 1 (2.8) |
| S | 1 (100) | 1 (100) | 2 (100) | 2 (18.2) | 12 (33.3) |
| Cephalexin | |||||
| R | 0 | 1 (100) | 0 | 9 (81.8) | 30 (83.3) |
| I | 0 | 0 | 0 | 2 (18.2) | 2 (5.6) |
| S | 1 (100) | 0 | 2 (100) | 0 | 4 (11.1) |
| Ofloxacin | |||||
| R | NA | 1 (100) | 0 | NA | NA |
| I | NA | 0 | 1 (50) | NA | NA |
| S | NA | 0 | 1 (50) | NA | NA |
| Azithromycin | |||||
| R | NA | 10 (100) | NA | NA | NA |
| I | NA | 0 | NA | NA | NA |
| S | NA | 0 | NA | NA | NA |
| Ampicillin | |||||
| R | NA | 1 (100) | 1 (50) | NA | NA |
| I | NA | 0 | 0 | NA | NA |
| S | NA | 0 | 1 (50) | NA | NA |
a Data are presented as No. (%).
| Isolates/Antibiotics | Acinetobacter spp. (Total No: 6) | E. coli (Total No: 5) | Enterobacter spp. (Total No: 5) | Klebsiella spp. (Total No: 3) | Pseudomonas spp. (Total No: 4) |
|---|---|---|---|---|---|
| Ceftizoxime | |||||
| R | 6 (100) | 2 (40) | 5 (100) | 3 (100) | 4 (100) |
| I | 0 | 0 | 0 | 0 | 0 |
| S | 0 | 3 (60) | 0 | 0 | 0 |
| Tetracycline | |||||
| R | 5 (83.3) | 5 (100) | 5 (100) | 3 (100) | 4 (100) |
| I | 1 (16.7) | 0 | 0 | 0 | 0 |
| S | 0 | 0 | 0 | 0 | 0 |
| Amikacin | |||||
| R | 5 (83.3) | 2 (40) | 5 (100) | 2 (66.7) | 2 (50) |
| I | 0 | 0 | 0 | 1 (33.3) | 0 |
| S | 1 (16.7) | 3 (60) | 0 | 0 | 2 (50) |
| Chloramphenicol | |||||
| R | 6 (100) | 4 (80) | 0 | 2 (66.7) | 4 (100) |
| I | 0 | 0 | 0 | 0 | 0 |
| S | 0 | 1 (20) | 5 (100) | 1 (33.3) | 0 |
| Ciprofloxacin | |||||
| R | 5 (83.3) | 2 (40) | 0 | 1 (33.3) | 0 |
| I | 0 | 0 | 1 (20) | 1 (33.3) | 1 (25) |
| S | 1 (20) | 3 (60) | 4 (60) | 1 (33.3) | 3 (75) |
| Gentamycin | |||||
| R | 5 (83.3) | 3 (60) | 5 (100) | 3 (100) | 1 (25) |
| I | 0 | 0 | 0 | 0 | 0 |
| S | 1 (16.7) | 2 (40) | 0 | 0 | 3 (75) |
| Cefixime | |||||
| R | 6 (100) | 4 (80) | 5 (100) | 3 (100) | 4 (100) |
| I | 0 | 0 | 0 | 0 | 0 |
| S | 0 | 1 (20) | 0 | 0 | 0 |
| Cephalexin | |||||
| R | 6 (100) | 5 (100) | 5 (100) | 3 (100) | 4 (100) |
| I | 0 | 0 | 0 | 0 | 0 |
| S | 0 | 0 | 0 | 0 | 0 |
| Co-trimoxazole | |||||
| R | 5 (83.3) | 3 (60) | 5 (100) | 2 (66.7) | 4 (100) |
| I | 1 (16.7) | 0 | 0 | 0 | 0 |
| S | 0 | 2 (40) | 0 | 1 (33.3) | 0 |
| Imipenem | |||||
| R | 5 (83.3) | NA | NA | NA | NA |
| I | 0 | NA | NA | NA | NA |
| S | 1 (16.7) | NA | NA | NA | NA |
a Data are presented as No. (%).